Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials

Abstract

© 2018 American College of Cardiology Foundation The number of persons with heart failure has continued to rise over the last several years. Approximately one-half of those living with heart failure have heart failure with preserved ejection fraction, but critical unsolved questions remain across the spectrum of basic, translational, clinical, and population research in heart failure with preserved ejection fraction. In this study, the authors summarize existing knowledge, persistent controversies, and gaps in evidence with regard to the understanding of heart failure with preserved ejection fraction. Our analysis is based on an expert panel discussion “Think Tank” meeting that included representatives from academia, the National Institutes of Health, the U.S. Food and Drug Administration, the Centers for Medicare & Medicaid Services, and industry.

Department

Description

Provenance

Subjects

Citation

Published Version (Please cite this version)

10.1016/j.jchf.2018.06.008

Publication Info

Parikh, Kishan S, Kavita Sharma, Mona Fiuzat, Howard K Surks, Jyothis T George, Narimon Honarpour, Christopher Depre, Patrice Desvigne-Nickens, et al. (2018). Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. JACC: Heart Failure, 6(8). pp. 619–632. 10.1016/j.jchf.2018.06.008 Retrieved from https://hdl.handle.net/10161/17286.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Parikh

Kishan S Parikh

Adjunct Associate in the Department of Medicine

Duke University Medical Center
Duke Clinical Research Institute

Mona Fiuzat

Adjunct Associate Professor in the Department of Medicine
O'Connor

Christopher Michael O'Connor

Adjunct Professor in the Department of Medicine

Dr. O’Connor’s research interests include: acute heart failure; co-morbidities in heart failure; clinical trials; biomarkers; and novel pharmacological and non-pharmacological approaches for the treatment of heart failure.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.